Tianjin Meihua biomedical technology Co.,Ltd.

Primary objective: To evaluate the bioequivalence of the test preparation diclofenac sodium sustained-release tablets produced by Tianjin Meihua Biopharmaceutical Technology Co., Ltd. and the reference preparation diclofenac sodium sustained-release tablets (Voltarene® LP) held by Novartis Pharma S.A.S. in healthy subjects after oral administration in fasting and fed state. Secondary objective: To observe the safety of the test preparation diclofenac sodium sustained-release tablets and the reference preparation diclofenac sodium sustained-release tablets (Voltarene® LP) in healthy subjects.

The diclofenac sodium double-release enteric-coated capsules provided by Tianjin Meihua Biopharmaceutical Technology Co., Ltd. were used as the test preparation. According to the relevant provisions of the bioequivalence test, the absorption rate and degree of diclofenac sodium double-release enteric-coated capsules (trade name: Difen®, reference preparation) produced by Temmler Ireland Ltd. were compared in healthy humans to investigate the human bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation diclofenac sodium double-release enteric-coated capsules and the reference preparation diclofenac sodium double-release enteric-coated capsules (Difen®) in healthy subjects.

Primary objective: To evaluate whether the test preparation indapamide sustained-release tablets (specification: 1.5 mg) produced by Tianjin Meihua Biopharmaceutical Technology Co., Ltd. and the reference preparation indapamide sustained-release tablets (trade name: Natali®, specification 1.5 mg) produced by Servier (Tianjin) Pharmaceutical Co., Ltd. are bioequivalent after oral administration in healthy subjects in fasting and postprandial states. Secondary objective: To observe the safety of the test preparation indapamide sustained-release tablets and the reference preparation indapamide sustained-release tablets in healthy subjects.